Liao, NJ
Baisong Liao, Highland Park, NJ US
Patent application number | Description | Published |
---|---|---|
20120004285 | ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY - The invention relates to pharmaceutical compositions for and methods of treatment with HER3-targeted combination therapy. The invention relates to pharmaceutical compositions comprising an oligomer which targets HER3 (and optionally one or more of HER2 and EGFR) mRNA in a cell, leading to reduced expression of HER3 and optionally HER2 and/or EGFR, and a small molecule protein tyrosine kinase inhibitor of one or more receptor tyrosine kinases, leading to inhibition of signaling and/or internalization of receptor dimers into the cell. The combination therapy is beneficial for a range of medical disorders, such hyperproliferative disorders (e.g., cancer). The invention provides methods of treating hyperproliferative disorders with a combination of an oligomer and a protein tyrosine kinase inhibitor. | 01-05-2012 |
Chaokuo Liao, Moorestown, NJ US
Patent application number | Description | Published |
---|---|---|
20090276977 | SELECTIVELY LOCKABLE CASTER - A selectively lockable caster with total locking (wheel brake and swivel lock) as well as directional locking (tracking) functions. A separate lock tooth for each locking function is adapted to engage certain differently configured lock recesses. Specifically, a total lock tooth, which is part of a mechanism that also applies a brake to the wheel, is configured to engage any of the total lock recesses and any of the directional lock recesses to lock the wheel against pivotal movement about the swivel axis in any of a plurality of total lock positions. A directional lock tooth is configured to engage only the directional lock recesses to lock the yoke against pivotal movement about the swivel axis in at least one directional lock (tracking) position while allowing the wheel to rotate. | 11-12-2009 |
Guo-Juan Liao, Edison, NJ US
Patent application number | Description | Published |
---|---|---|
20100227344 | METHODS FOR MEASURING ADP - This invention relates to assays for detecting and measuring ADP. In particular, this invention provides homogeneous luminescent assays that detect ADP generation and measures ADP accumulation based on enzymatic coupling reactions. The assays of the present invention can be applied to all types of kinases and other ADP-generating enzymes, are antibody free, beads free, radioisotope free, and compatible with commonly used kinase buffers. | 09-09-2010 |
Hongbiao Liao, Rahway, NJ US
Patent application number | Description | Published |
---|---|---|
20150203843 | NOVEL TETRAGALNAC CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES - Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; and optionally, 4) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents. | 07-23-2015 |
Hongbiao Liao, Bridgewater, NJ US
Patent application number | Description | Published |
---|---|---|
20100029939 | PREPARATION OF KETONE AMIDES - The present invention discloses a novel process to prepare ketone amides, which are useful intermediates for the preparation of antagonists of CCR5 receptor and therefore useful for the treatment of HIV virus infected mammals. It specifically discloses a novel process to synthesize 1-(2,4-dimethylpyrimidine-5-carbonyl)-4-piperidone, 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4-piperidone and related compounds. A salient feature of the invention is the use of a three-phase reaction medium with an organic phase and a buffer salt slurry. | 02-04-2010 |
20100249411 | Stereoselective Alkylation of Chiral 2-Methly-4 Protected Piperazines - In an illustrative embodiment, the present invention describes the synthesis of the following compound and similar compounds, in high stereochemical purity by a novel stereoselective alkylation process: | 09-30-2010 |
20120065397 | PREPARATION OF KETONE AMIDES - The present invention discloses a novel process to prepare ketone amides, which are useful intermediates for the preparation of antagonists of CCR5 receptor and therefore useful for the treatment of HIV virus infected mammals. It specifically discloses a novel process to synthesize 1-(2,4-dimethylpyrimidine-5-carbonyl)-4-piperidone, 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4-piperidone and related compounds. A salient feature of the invention is the use of a three-phase reaction medium with an organic phase and a buffer salt slurry. | 03-15-2012 |
20120178942 | ENANTIO- AND STEREO-SPECIFIC SYNTHESES OF BETA-AMINO-ALPHA- HYDROXY AMIDES - Processes useful for the preparation of a Compound of Formula I: Formula (I). Intermediates useful for the preparation of the compound of Formula I, and processes useful for preparing said intermediates are disclosed. | 07-12-2012 |
20130178541 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY - The instant invention provides for novel catiomc lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA. | 07-11-2013 |
I-Chien Liao, Princeton, NJ US
Patent application number | Description | Published |
---|---|---|
20150282925 | DECELLULARIZED MUSCLE MATRIX - Disclosed herein are muscle implants and methods of making muscle implants comprising one or more decellularized muscle matrices. The muscle matrices can, optionally, be joined to one or more decellularized dermal matrices. The muscle implants can be used to enhance muscle volume or to treat muscle damage, defects, and/or disorders. The decellularized muscle matrices in the implants retain at least some of the myofibers found in a muscle tissue prior to processing. | 10-08-2015 |
Jing Liao, Edison, NJ US
Patent application number | Description | Published |
---|---|---|
20090281321 | EXO- AND DIASTEREO- SELECTIVE SYNTHESES OF HIMBACINE ANALOGS - This application discloses a novel process for the preparation of himbacine analogs useful as thrombin receptor antagonists. The process is based in part on the use of a base-promoted dynamic epimerization of a chiral nitro center. The chemistry taught herein can be exemplified by the following: | 11-12-2009 |
20110251392 | EXO- AND DIASTEREO- SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS - This application discloses a novel process for the preparation of himbacine analogs useful as thrombin receptor antagonists. The process is based in part on the use of a base-promoted dynamic epimerization of a chiral nitro center. The chemistry taught herein can be exemplified by the following: | 10-13-2011 |
20120296093 | EXO- AND DIASTEREO- SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS - This application discloses a novel process for the preparation of himbacine analogs useful as thrombin receptor antagonists. The process is based in part on the use of a base-promoted dynamic epimerization of a chiral nitro center. The chemistry taught herein can be exemplified by the following: | 11-22-2012 |
Jing Liao, Livingston, NJ US
Patent application number | Description | Published |
---|---|---|
20090203925 | SYNTHESIS OF HIMBACINE ANALOGS - The present invention relates to an improved process for preparing himbacine analogs. The compounds are useful as thrombin receptor antagonists. The improved process may allow for at least one of easier purification by crystallization, easier scalability, and improved process yield on the desired enantiomer. | 08-13-2009 |
20090203936 | SYNTHESIS OF 3-(5-NITROCYCLOHEX-1-ENYL) ACRYLIC ACID AND ESTERS THEREOF - This application discloses provides a process for the introduction of nitro-group functionality into a compound which contains also a site of unsaturation and/or oxygen functionality by direct (one step) oxidation of an oxime functional group mediated by a molybdenum VI/VII peroxo complex, the process comprising: | 08-13-2009 |
20130253135 | POLY(AMIDE) POLYMERS FOR THE DELIVERY OF OLIGONUCLEOTIDES - The present invention provides poly(amide) polymers, polyconjugates, compositions and methods for the delivery of oligonucleotides for therapeutic purposes. | 09-26-2013 |
Jun Liao, Cedar Knolls, NJ US
Patent application number | Description | Published |
---|---|---|
20120189666 | PHARMACEUTICAL FORMULATIONS CONTAINING MICROPARTICLES OR NANOPARTICLES OF A DELIVERY AGENT - This invention relates to microparticles and/or nanoparticles containing a delivery agent and/or an active agent. This invention also relates to pharmaceutical formulations and solid dosage forms, including controlled release solid dosage forms of active agent and a delivery agent. | 07-26-2012 |
20150190344 | FORMULATIONS FOR DELIVERING INSULIN - Oral insulin formulations and processes for preparing oral insulin formulations are provided. | 07-09-2015 |
Linxia Liao, Plainsboro, NJ US
Patent application number | Description | Published |
---|---|---|
20130060524 | Machine Anomaly Detection and Diagnosis Incorporating Operational Data - A method for detecting an anomaly in a machine under test includes monitoring operational data from a control unit of the machine under test. An operational state of the machine under test is identified based on the monitored operational data. Sensor data is monitored from one or more sensors installed within or near to the machine under test. A model corresponding to the identified operational state of the machine under test is consulted to identify one or more key parameters and corresponding normal operating ranges for each determined key parameter. It is determined when a key parameter of the one or more key parameters is not within its corresponding normal operating range based on the monitored sensor data. | 03-07-2013 |
20130197854 | SYSTEM AND METHOD FOR DIAGNOSING MACHINE TOOL COMPONENT FAULTS - A machine tool system is diagnosed by identifying a fault class to which an input measurement vector belongs. The fault class corresponds to a group of weight vectors in a code book of a self organized map that describes the machine tool system based on training data. Probabilities that the input measurement vector belongs to a given class are estimated based on the posterior probability of the weight vectors of the code book corresponding to the given class given the input measurement vector. Training data to create the code book may be collected under a first operating condition while the input measurement vector is collected under a second operating condition. | 08-01-2013 |
20140039806 | ESTIMATING REMAINING USEFUL LIFE FROM PROGNOSTIC FEATURES DISCOVERED USING GENETIC PROGRAMMING - A method for estimating a remaining useful life of a system includes monitoring sensor data from sensors deployed within a system. A plurality of features are extracted from the sensor data. Tree graphs are generated including mathematical operators and features as nodes and a advanced feature is produced from each of the tree graphs by transforming the tree graphs into equations. A recursive operation including analyzing a fitness of each of the advanced features, performing crossover/mutation on the tree graphs, producing advanced features from the altered tree graphs, and analyzing the fitness of the altered tree graphs to produce at least one final advanced feature is performed. A remaining useful life of the system is calculated based on the final advanced feature. | 02-06-2014 |
Linxia Liao, Mountain View, NJ US
Patent application number | Description | Published |
---|---|---|
20150073751 | Embedded Prognostics on PLC Platforms for Equipment Condition Monitoring, Diagnosis and Time-to-Failure/Service Prediction - A prognostics analysis software module is embedded in a programmable logic controller (PLC) software platform. During cycling of the PLC real-time operating program, data is read from sensors and written to a buffer only when the prognostics analysis software module is idle. The prognostics analysis software module is then activated by a system function block of the PLC software platform. Before determining any prognostic information, prediction models within the prognostics analysis software module are automatically trained using features extracted from the sensor data. | 03-12-2015 |
Shyhyuan Liao, West Windsor, NJ US
Patent application number | Description | Published |
---|---|---|
20100285201 | SYNERGISTIC SWEETENING COMPOSITIONS - A sweetening composition comprising sucralose and a purified extract of stevia. | 11-11-2010 |
20140044852 | SWEETENER CRYSTALS AND METHOD OF MAKING - A sweetening composition comprising a crystalline matrix wherein the crystalline matrix comprises a high intensity sweetener and a carrier/substrate, and wherein the composition has a bulk density of about 0.4 g/cc to about 1.0 g/cc. | 02-13-2014 |
20150030547 | PARTIAL MELT CO-CRYSTALLIZATION COMPOSITIONS - A co-crystallization composition containing erythritol and an active; a method of making the co-crystallization composition; and a method of using the co-crystallization composition are disclosed. | 01-29-2015 |
Xibin Liao, Edison, NJ US
Patent application number | Description | Published |
---|---|---|
20100216694 | ANTIDIABETIC TRICYCLIC COMPOUNDS - Tricyclic compounds containing a cyclopropanecarboxylic acid fused to a bicyclic ring, including pharmaceutically acceptable salts, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. | 08-26-2010 |
20110172256 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE - Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included. | 07-14-2011 |
20110251248 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS - Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included. | 10-13-2011 |
20110306624 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE - Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included. | 12-15-2011 |
20110312911 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE - Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included. | 12-22-2011 |
20130072492 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS - A compound of Formula (I): or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula (I) or a pharmaceutically acceptable salt thereof. | 03-21-2013 |
Yun Liao, Glen Rock, NJ US
Patent application number | Description | Published |
---|---|---|
20130177529 | Pyrazole Compounds - Aryl substituted pyrazole derivatives are provided, as well as processes for their preparation. The invention also provides compositions and methods for the treatment of HCV by administering a compound of the present invention, alone or in combination with additional antiviral agents, in a therapeutically effective amount. | 07-11-2013 |
Yun Liao, Glenrock, NJ US
Patent application number | Description | Published |
---|---|---|
20090041723 | Compounds and methods for treatment of HCV - Aryl substituted pyrazole derivatives are provided, as well as processes for their preparation. The invention also provides compositions and methods for the treatment of HCV by administering a compound of the present invention, alone or in combination with additional antiviral agents, in a therapeutically effective amount. | 02-12-2009 |